Safety and effectiveness of a 300 IR house dust mite sublingual tablet: descriptive 4-year final analysis of a post-marketing surveillance in Japan. Supplementary data

Supplementary table 1. Outcomes at the last recorded visit in evaluable patients who were discontinued/terminated from the study for failing to attend hospital visits.